Background-The safety and efficacy of new-generation drug-eluting stents (DES) in women with multiple atherothrombotic risk (ATR) factors is unclear. Methods and Results-We pooled patient-level data for women enrolled in 26 randomized trials. Study population was categorized based on the presence or absence of high ATR, which was defined as having history of diabetes mellitus, prior percutaneous or surgical coronary revascularization, or prior myocardial infarction. The primary end point was major adverse cardiovascular events defined as a composite of all-cause mortality, myocardial infarction, or target lesion revascularization at 3 years of followup. Out of 10 449 women included in the pooled database, 5333 (51%) were at high ATR. Compared with women not at high ATR, those at high ATR had significantly higher risk of major adverse cardiovascular events (15.8% versus 10.6%; adjusted hazard ratio: 1.53; 95% confidence interval: 1.34-1.75; P=0.006) and all-cause mortality. In high-ATR risk women, the use of new-generation DES was associated with significantly lower risk of 3-year major adverse cardiovascular events (adjusted hazard ratio: 0.69; 95% confidence interval: 0.52-0.92) compared with early-generation DES. The benefit of new-generation DES on major adverse cardiovascular events was uniform between high-ATR and non-high-ATR women, without evidence of interaction (P interaction =0.14). At landmark analysis, in high-ATR women, stent thrombosis rates were comparable between DES generations in the first year, whereas between 1 and 3 years, stent thrombosis risk was lower with new-generation devices. Conclusions-Use of new-generation DES even in women at high ATR is associated with a benefit consistent over 3 years of follow-up and a substantial improvement in very-late thrombotic safety. 1 Currently, atherothrombotic disorders of the coronary, cerebrovascular, and peripheral arterial vasculature are the leading cause of mortality worldwide. In fact, according to the American Heart Association, over 1.1 million Americans in 2010 were hospitalized with acute coronary syndrome.
A therothrombosis is a life-threatening condition in which rupture of a high-risk plaque can lead to thrombosis and occlusion of an artery, in turn causing symptoms of peripheral ischemia, stroke, or acute coronary syndrome. 1 Currently, atherothrombotic disorders of the coronary, cerebrovascular, and peripheral arterial vasculature are the leading cause of mortality worldwide. In fact, according to the American Heart Association, over 1.1 million Americans in 2010 were hospitalized with acute coronary syndrome. 1, 2 Importantly, about 488 000 of these patients were women. 2 Women also constitute about one third of all patients treated with percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. 2 However, women have been underrepresented in randomized controlled trials (RCTs) that investigated the safety and efficacy of DES. In the 2011 Food and Drug Administration's guidance document, gender disparities in RCTs investigating medical devices were identified and addressed. In response to the recommendations expressed by the Food and Drug Administration, the Society for Cardiovascular Angiography and Interventions' Women in Innovation Initiative organized a Gender Data Forum in which the outcomes of DES in women were addressed. This led to the creation and analysis of the present large individual female patient-level pooled data set from existing randomized trials of DES.
Although trials investigating pharmacotherapies targeting key molecular and cellular players in the pathogenesis of arterial thrombosis have been conducted in patients with multiple atherothrombotic risk (ATR) factors, [3] [4] [5] to date, few data are available regarding the relative safety and efficacy of newgeneration DES in such a high-risk population, especially of female sex. With the hypothesis that presence of durable multiple ATR factors might attenuate the benefits associated with new-generation DES, in the present patient-level pooled analysis of RCTs, we sought to evaluate the prognostic impact of a study-defined high-ATR in women undergoing PCI and the safety and efficacy of new-generation DES, compared with early-generation, in women with or without high ATR.
Methods

Study Design and Population
The rationale of the present patient-level pooled database, list of trials, analytic strategies, and prespecified end points has been previously reported. 6 Briefly, female participants from 26 RCTs were pooled: RAVEL ( 
WHAT IS KNOWN
• Concomitance of multiple atherothrombotic risk factors enhance propensity for coronary ischemic events and mortality.
• Increased platelet inhibition is beneficial in patients at high risk for atherothrombotic events. However, whether the improved biocompatibility and antithrombotic properties of new-generation drug-eluting stent are preserved in women at high atherothrombotic risk is unknown.
WHAT THE STUDY ADDS
• In women at high atherothrombotic risk, compared with early-generation drug-eluting stent, new-generation devices are associated with preserved safety and efficacy over 3 years of follow-up and with a substantial benefit in very-late (>1 year) stent-related thrombotic safety.
• In women not at high atherothrombotic risk, newgeneration drug-eluting stents were associated with an exceedingly low risk of very-late (>1 year) stent thrombosis at 3 years of follow-up. DES in Women at High Risk for Atherothrombosis in the Data Supplement). Characteristics of the RCTs included in the present study are summarized in the Table I in the Data Supplement. All the included RCTs were performed between 2000 and 2013. The study population was stratified into 2 categories based on the presence or absence of high ATR (Table 1) . Women who received a bare-metal stent were excluded from this analysis. ATR was defined as the composite of history of diabetes mellitus (DM), previous revascularization (PR; defined as previous PCI or previous coronary artery bypass graft), or previous myocardial infarction (PMI). The rationale of such definition is based on the criteria used in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) 3 according to the available clinical variables included in the pooled data set. Moreover, each one of these risk factors previously demonstrated to be associated with substantial increased risk for adverse events in patients undergoing PCI. [7] [8] [9] All trials included in our analysis complied with the provisions of the Declaration of Helsinki, and the institutional review board at each study center approved the study protocols. All patients provided written informed consent for participation in each study.
Drug-Eluting Stents
The following DES have been included in the present analysis: sirolimus-eluting stents (Cypherand Cordis, Johnson & Johnson, Miami Lakes, FL), paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, MA), everolimus-eluting stents (Xience, AbbottVascular, Santa Clara, CA; Promus, Boston Scientific), zotarolimus-eluting stents (Endeavor, Medtronic, Santa Rosa, CA; Resolute, Medtronic), biolimus-eluting stents with biodegradable polymer coating (Biomatrix, Biosensors, Newport Beach, CA; Nobori, Terumo, Tokyo, Japan), and sirolimus-eluting stents with biodegradable polymer coating (Yukon, Translumina, Hechingen, Germany).
Coronary stents used among trials were classified as early-generation DES (including sirolimus-and paclitaxel-eluting stents) and new-generation DES (including everolimus and zotarolimus stents 
Study Objectives and End Points Definitions
The objectives of the present study were (1) to characterize the impact of multiple ATR factors on outcomes in women undergoing PCI with DES and (2) to evaluate the safety and efficacy of new-generation DES, compared with earlier generation, in women at high ATR. The primary end point of the current study was the risk of major adverse cardiac events (MACE). MACE was defined as the composite of allcause mortality, myocardial infarction (MI), or target-lesion revascularization. Additional end points were the individual components of MACE, cardiac mortality, definite or probable stent thrombosis (ST), and the composite of all-cause mortality, MI, or definite or probable ST. The clinical end point definitions used across trials are detailed in Table II in the Data Supplement.
Statistical Analysis
All patient-level data were aggregated and combined as one data set on a prespecified extraction sheet. Baseline clinical, demographic, and procedural characteristics of the study groups were reported as mean±standard deviation for continuous variables and as proportions for categorical variables. Continuous variables were compared with student t test. Categorical variables were compared with χ 2 test. Cumulative event rates in the study groups were calculated with the Kaplan-Meier method and compared with the log-rank test. For these analyses, the total follow-up was defined as the time from index procedure until death, last follow-up date, or 3 years, whichever came first. Additionally, we performed Kaplan-Meier analyses in the landmark periods of zero to 1 year and of 1 to 3 years to evaluate the impact of DES generation on thrombotic end points at different time periods. The independent associations between high ATR, stent generation, and outcomes were assessed with the Cox proportional hazards models that included a frailty term (γ) to assess random effects in the trials. Frailties are the unmeasured factors that affect trialspecific baseline risk and are distributed as γ random variables with a mean of 1 and variance θ. The variance parameter was interpreted as a metric of heterogeneity in baseline risk between trials. In the adjusted analysis evaluating the impact of high ATR on outcomes, no high ATR was the reference category. For the DES-level analysis, early-generation DES was the reference category. Multivariable models included covariates that significantly differed at univariate analysis and those deemed clinically relevant from previous studies (without including variables that are intrinsically part of the composite ATR definition). The full list of covariates included in the multivariable models is listed in the footnotes of the tables. The proportionality assumption was verified by means of scaled Schoenfeld residual.
Multicollinearity was evaluated by means of visual inspection of correlation matrix and estimation of the variance inflation factor, with >10 used as a threshold to define significant multicollinearity. For the DES-level analysis, the consistency of the effect of new-generation DES in women with or without high ATR was evaluated with formal interaction test. We judged P values of <0.05 to be significant, and all analyses were done with SAS software.
Results
Baseline Characteristics
Out of 10 449 women included in the pooled database, 5333 (51%) were at high ATR ( Figure 1 ). Clinical characteristics according to high ATR are reported in Table 1 . Women with high ATR were older, had higher body mass index, and had greater prevalence of arterial hypertension and hypercholesterolemia. Patterns of clinical presentation significantly differed between groups: women at high ATR had more stable phenotypes and women without high ATR had higher prevalence of MI presentation. Angiographic and procedural data are reported in Table 1 . Women with high ATR had a higher number of lesions treated, stents implanted, American College of Cardiology/American Heart Association type B2/C lesions, moderate or severe calcifications, and greater total stent length.
Impact of High ATR Status on 3-Year Clinical Outcomes
Unadjusted and adjusted clinical outcomes according to high-ATR status are reported in Table 2 . A significantly higher crude rate of MACE was observed in women with versus without high ATR (Figure 2A ; 15.8 % versus 10.6%; P<0.0001). Women with high ATR also had higher rates of all-cause mortality ( Figure 2B ), cardiac mortality, MI, target-lesion revascularization, definite or probable ST, and the composite of all-cause mortality, ST, or MI.
Following multivariable adjustment, high ATR status was independently associated with higher risk of MACE (adjusted hazard ratio [ 
Early-Versus New-Generation DES in Women at High ATR
Three-year outcomes according to ATR status and DES generation are reported in Table 3 and Figure 4 . In women with high ATR, the use of new-generation DES was associated with significantly lower risk of MACE at 3 years (adjusted HR: 0.79; 95% CI: 0.63-0.99) compared with early-generation DES ( Table 3) . As well, compared with early-generation DES, use of new-generation devices was associated with a significant benefit in cardiac mortality (adjusted HR: 0.52; 95% CI: 0.31-0.88), MI (adjusted HR: 0.68; 95% CI: 0.47-0.98), and the composite of all-cause mortality, ST, or MI (adjusted HR: 0.69; 95% CI: 0.52-0.92). The effects of new-generation DES on outcomes were uniform between high-ATR and non-high-ATR women, without evidence of interaction. Additionally, the effect of new-generation DES on the risk of MACE (Figure I in the Data Supplement) and death, MI, or ST ( Figure II in the Data Supplement) were uniform across markers of anatomical and procedural complexity, in a magnitude that was overall similar with the one observed between high-ATR and non-ATR groups.
Kaplan-Meier analyses in the landmark periods for thrombotic end points according ATR status and DES generation are illustrated in Figure 5A (composite of all-cause mortality, MI, or ST) and 5B (ST). A significantly lower risk of all-cause mortality, MI, or ST and ST was observed within both zero and 1 year and between 1 and 3 years with new-generation DES in women not at high ATR. Of note, in women not at high ATR, rates of ST were low within both the first year (0.5%) and between 1 and 3 years (0.1%). In women at high ATR, rates of ST in the first year with new-generation DES approximated those observed with early-generation devices; conversely, after 1 year, new-generation DESs were associated with improved very-late ST safety compared with earlygeneration DES ( Figure 5B ).
Discussion
To the best of our knowledge, this is the first large report with patient-level data from RCTs investigating the safety and efficacy of early-and new-generation DES in women at high risk for atherothrombosis undergoing PCI. The main findings of our study are the following: (1) the presence of multiple ATR factors is associated with increased long-term risk of MACE and mortality after DES implantation in women; among these, ATR indicates atherothrombotic risk; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiac events; MI, myocardial infarction; ST, stent thrombosis; and TLR, target-lesion revascularization.
*Log-rank P value. †Variables included in the model were age, body mass index, hypertension, dyslipidemia, family history of CAD, smoking, presentation with an acute coronary syndrome, stent generation, serum creatinine, stent length, and type B2 or C lesions. Hazard ratio expressed with No High-ATR as the reference group.
‡Wald P value. Figure 2 . Cumulative Kaplan-Meier curves for major adverse cardiac events (A) and all-cause mortality (B) at 3 years in women according to ATR status. P value from log-rank test. ATR indicates atherothrombotic risk. DES in Women at High Risk for Atherothrombosis DM was the only one independently associated with higher MACE and mortality risk; combination of ≥2 risk factors confers an additive hazard on long-term adverse events; (2) compared with early-generation DES, use of new-generation DES is associated with consistent benefit on adverse outcomes in women, irrespective of ATR status; in particular, in high-ATR women, antithrombotic properties of new-generation devices seem to be more evident between one and three years, rather within the first year post-PCI; (iii) women not at high-ATR treated with new-generation DES had low risk of very-late ST at 3 years of follow-up. Although early-generation DES significantly improved the efficacy of PCI compared with bare metal stent, newgeneration platforms substantially enhanced the safety of intracoronary stent implantation by mitigating the risk of late and very-late platform thrombosis. 10 Concerns regarding the unrestricted use of DES were mainly because of the higher risk of ST observed in high-risk patients or high-risk coronary lesions. 11 Although studies, such as the Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE), 12 a substudy from CHARISMA in high-risk patients, 13 and others, 4 ,5 demonstrated an improved anti-ischemic efficacy with lower risk of adverse cardiac events in high-ATR patients with addition of higher potency antiplatelet agents, such evidence with new-generation DES, and in particular in women, is poor. In the present analysis, we sought to expand the existing evidence by evaluating the impact of high ATR on clinical outcomes in women undergoing PCI with DES and by investigating whether the benefits of new-generation DES are maintained in women with and without high-ATR status.
ATR and Outcomes in Women Undergoing PCI
Study-defined high ATR was associated with greater coronary artery disease (CAD) severity and complexity and a substantial crude and independent increased risk of MACE, mortality, and each single ischemic end point in women after DES implantation. Among the available variables in the pooled data set, we opted to use 3 well-defined risk factors for future adverse events (DM, PR, and PMI) to identify patients at high ATR, given the solid supporting literature and their pathobiological direct or indirect role in atherothrombosis. [3] [4] [5] 13 Among the available baseline clinical variables, we did not opt to include clinical presentation within ATR definition because we previously demonstrated that most of the risk in women associated with increased acuteness and severity of CAD across its clinical spectrum appears to be confined within 1 year to then decay over time.
14 Conversely, the included clinical variables might have a more durable effect on the risk of adverse events after Cumulative Kaplan-Meier curves for major adverse cardiac events (A) and all-cause mortality (B) at 3 years in women according to the atherothrombotic risk factor. P value from log-rank test. ATR indicates atherothrombotic risk; CABG, coronary artery bypass graft; MI, myocardial infarction; and PCI, percutaneous coronary intervention. DES in Women at High Risk for Atherothrombosis PCI. We did not include smoking status because the definition of current smoking was not available and because the relationship between smoking and adverse outcomes is uncertain. 15 However, although the combination of these risk factors showed an additive effect on the risk of adverse events, only DM exhibited an increased and independent risk on MACE and mortality. The lack of independent effect of PR and PMI might be related to the fact that these 2 clinical variables are a reflection of the burden and severity of CAD rather than a direct mediator of the overall clinical risk. Although DM is directly involved in the pathogenesis of chronic kidney disease, endocrine dysfunction, increased thrombogenicity, peripheral arterial disease, and cerebrovascular disease, 16 the nature of the crude relationship between PR and PMI with adverse outcomes is most likely correlative rather than causative.
New-Generation DES in Women at High Risk for Atherothrombosis
By optimizing vascular biocompatibility, endothelialization with strut coverage, and drug release kinetic, compared with earlygeneration DES, new-generation DES significantly improved the late and very-late safety of intracoronary DES implantation.
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Figure 4. Cumulative Kaplan-Meier curves for major adverse cardiac events (A), the composite of all-cause mortality, myocardial infarction (MI), or stent thrombosis (B), and definite or probable stent thrombosis (C) at 3 years according to atherothrombotic risk status and drug-eluting stent generation. P value from log-rank test. ATR indicates atherothrombotic risk; and DES, drug-eluting stent. at Universitaetsbibliothek Bern on April 20, 2016 http://circinterventions.ahajournals.org/ Downloaded from DES in Women at High Risk for Atherothrombosis However, whether these benefits are maintained in the high-risk patient subset, in particular of female sex, is to date unclear. In women at high ATR, at 3 years, we observed a significant benefit with new-generation DES across all the studied ischemic outcomes, including cardiac mortality. Moreover, when we looked at the relative temporal distribution of event rates through 3 years, most of the stent-related thrombotic benefit was confined to the very-late period (1 to 3 years) . In fact, the benefits of newgeneration DES over early-generation DES in high-ATR women appear to be related to a substantial improvement in the very-late safety, whereas the event rates remain high early after PCI in this patient subset. Notably, the rates of ST were exceedingly low in women not at high ATR, especially between 1 and 3 years (0.1%). These findings have several important clinical implications: (1) in a contemporary practice with new-generation DES, women with CAD at lower risk for atherothrombosis might not benefit from prolonged (beyond 6 months or 1 year) dual antiplatelet therapy to prevent stent-related thrombotic complications; instead, these would expose such patients to an unnecessary bleeding and possibly mortality risk 17, 18 ; (2) conversely, women with high ATR, even with new-generation DES, remain at high risk for stent-related ischemic complications in the first year after PCI, suggesting that completion of at least 1 year of a regimen of dual antiplatelet inhibition might be appropriate in this patient subset in presence of low risk of bleeding. Considering that the presence of chronic ATR factors yields a constant risk over time to develop coronary thrombotic events (both stent-and non-stent-related), 19 the benefits associated with use of new-generation DES in this high-risk population are more likely to be observed over long-term follow-up rather than early after PCI. Therefore in presence of a favorable efficacy (antiischemic) and safety (prohemorrhagic) trade-off, high-ATR women might benefit from more potent and prolonged (>1 year) platelet inhibition which should be applied with the rationale of preventing cerebrovascular, peripheral, and non-DES-related coronary atherothrombotic events, rather than those occurring within the coronary vascular segment where a new-generation DES has been implanted.
Limitations
Notwithstanding our findings rely on individual patient-level, high-quality data from prospective, randomized trials with data monitoring and event adjudication by clinical event committees, several limitations have to be disclosed. First, atherothrombosis is a systemic disease so other clinical variables characterize this condition; however, important clinical variables, such as documented cerebrovascular disease, documented symptomatic peripheral arterial disease, carotid artery disease, diabetic nephropathy (baseline serum creatinine was available only in half of the study population), and uncontrolled arterial hypertension or hypercholesterolemia, were not available in the pooled data set; therefore, our study-defined population is more likely a high-cardiac-ATR rather than a high-systemic-ATR; however, the benefits of new-generation DES would be cardiac in nature as opposed to an antiplatelet agent that would confer a systemic effect and, therefore, acting also on noncoronary arterial vasculature. Second, some trials included in the analysis were performed more than a decade ago, during which clinical practice and device technology changed. To reduce the trial effect on outcomes, we included trial as a random effect in our adjusted analysis. Third, patient population across trials was heterogeneous; early trials focused only on stable CAD with simple lesion, whereas most recent trials had a tendency to include more complex patients and lesions subsets. Fourth, the exclusion of male participants from this study precludes sex-specific analysis, limiting the external validity of our findings. Fifth, this has to be considered as a post hoc analysis from RCTs not designed to specifically assess DES outcomes in women with high ATR. To overcome this limitation, we carried out a rigorous multivariable adjustment. However, as in any nonrandomized study, our findings are subject to residual confounding on the effect estimates.
Conclusions
Multiple risk factors for atherothrombosis are common in women with CAD undergoing PCI with DES and are associated with a substantial increased risk of MACE and mortality. Compared with early-generation DES, newer-generation DES are associated with a significantly improved safety and efficacy in women at high ATR at 3 years after PCI. Of note, in women at high ATR, the thrombotic benefit of new-generation DES appeared more evident in the verylate period rather than within 1 year after PCI. The rates of ST with new-generation DES in women not at high-ATR were low ≤3 years of follow-up. The results of the present patient-level pooled analysis underscore the significant benefits, and their temporal distribution, of new-generation DES in this high-risk subset of patients previously underrepresented in RCTs.
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